Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Accumulated Expenses (2019 - 2026)

Alx Oncology Holdings' Accumulated Expenses history spans 5 years, with the latest figure at $6.1 million for Q4 2023.

  • On a quarterly basis, Accumulated Expenses rose 63.62% to $6.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was $6.1 million, a 63.62% increase, with the full-year FY2023 number at $6.1 million, up 63.62% from a year prior.
  • Accumulated Expenses hit $6.1 million in Q4 2023 for Alx Oncology Holdings, up from $4.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for ALXO hit a ceiling of $16.6 million in Q3 2022 and a floor of $924000.0 in Q4 2019.
  • Historically, Accumulated Expenses has averaged $4.9 million across 5 years, with a median of $3.5 million in 2021.
  • Biggest five-year swings in Accumulated Expenses: soared 620.58% in 2022 and later plummeted 76.36% in 2023.
  • Tracing ALXO's Accumulated Expenses over 5 years: stood at $924000.0 in 2019, then surged by 113.64% to $2.0 million in 2020, then surged by 66.87% to $3.3 million in 2021, then rose by 12.57% to $3.7 million in 2022, then skyrocketed by 63.62% to $6.1 million in 2023.
  • Business Quant data shows Accumulated Expenses for ALXO at $6.1 million in Q4 2023, $4.0 million in Q3 2023, and $3.0 million in Q2 2023.